Table 5

ACT groups of suspected medications

ATC classAll incidentsIncidents with probable or definite relationship with medicationRelative risk
(percentages left by right column)
Swiss 2015 sales* (number of packages)
AAlimentary tract and metabolism28 (14.6%)6 (15.8%)1.0631 455 252 (14.9%)
BBlood and blood-forming organs23 (12.0%)7 (18.4%)7.085 507 624 (2.6%)
CCardiovascular system44 (22.9%)1 (2.6%)0.3516 027 143 (7.5%)
DDermatologics1 (0.5%)0 (0.0%)0.0017 314 810 (8.2%)
GGenitourinary system and sex hormones1 (0.5%)0 (0.0%)0.007 936 641 (3.7%)
HSystemic hormonal preparations (excluding sex hormones and insulins)7 (3.6%)1 (2.6%)2.002 875 760 (1.3%)
JAnti-infectives for systemic use23 (12.0%)6 (15.8%)3.958 444 623 (4.0%)
KInfusion liquids0 (0.0%)0 (0.0%)0.0024 158 749 (11.5%)
LAntineoplastic and immunomodulating agents5 (2.6%)1 (2.6%)2.891 934 950 (0.9%)
MMusculoskeletal system4 (2.1%)2 (5.3%)0.7614 787 413 (7.0%)
NNervous system43 (22.4%)10 (26.3%)1.3042 690 195 (20.2%)
PAntiparasitic products, insecticides and repellents1 (0.5%)0 (0.0%)0.004 62 559 (0.2%)
RRespiratory system7 (3.6%)3 (7.9%)0.5728 837 468 (13.7%)
SSensory organs2 (1.0%)0 (0.0%)0.007 658 311 (3.6%)
TDiagnostic use0 (0.0%)0 (0.0%)0.0043 184 (0.0%)
VVarious3 (1.6%)1 (2.6%)6.508 55 707 (0.4%)
Total192 (100.0%)38 (100%)1.0210 990 389 (100.0%)
Does not apply50n.a.n.a.
  • * Information by Interpharma Switzerland (see online Supplementary Appendix B).

  • Relative risk of drugs with probable or definite relationship with the incident as compared with sales proportions. 

  • n.a., not available.